Navigation Links
First NxStage® Home Hemodialysis Patients Celebrate Seven-Year Anniversary
Date:12/16/2010

LAWRENCE, Mass., Dec. 16, 2010 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that a group of its first patients are celebrating their seven-year anniversary of home hemodialysis treatment with the NxStage® System One™, the only hemodialysis machine cleared by the FDA for home use. Each of these patients continues to experience the improved health and quality of life benefits possible with more frequent home hemodialysis using the System One.

As early adopters of daily home hemodialysis with the NxStage System One, each of the patients arrived at the decision to try NxStage at various stages in his treatment for end stage renal disease (ESRD). These patients--Craig, Carl, and Everette--began treatment with the NxStage System One in December, 2003 as part of NxStage's groundbreaking clinical trial for its home indication.

Everette had been undergoing in-center dialysis treatments when he learned about daily home hemodialysis with NxStage. "For the past seven years, the NxStage System One has given me the freedom to live my life closer to the way I want to live it and allowed me to dedicate more time to my hobbies and business dreams," he said.  "Thanks in part to NxStage and dialyzing more frequently, I feel more healthy and active. I've come off several blood pressure medications and play basketball twice a week while spearheading my online clothing store."

"This is a tremendous milestone not only for these patients, but also for all of our patients, prescribing nephrologists, partners and employees," stated Jeffrey H. Burbank, founder and CEO of NxStage Medical, Inc. "We are extremely gratified to see these patients thriving and are excited to expand access to the life changing benefits possible with more frequent home hemodialysis using the System One to a growing number of patients worldwide."  

You can read more about these patients and others on the NxStage website at http://www.nxstage.com/our_community/chronic_community/patients/patient_stories.cfm.

About NxStage Medical, Inc.NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of End Stage Renal Disease (ESRD) and acute kidney failure. For more information on NxStage and its products, please visit NxStage's website at www.nxstage.com.

The patient testimonials included in this release are examples of patient experiences on home daily hemodialysis with the NxStage System One. All patient experiences will vary, and there can be no assurance that all patients will experience these benefits. All hemodialysis involves some risk, and patients are encouraged to speak with their physicians to see if home dialysis with the NxStage System One is right for them.

Forward-Looking StatementsThis release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors that are discussed in NxStage's Quarterly Report on Form 10-Q for the period ended September 30, 2010 filed with the SEC. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.Contact:Kristen K. Sheppard, Esq.VP, Investor Relationsksheppard@nxstage.com
'/>"/>

SOURCE NxStage Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Advanced Radiology Introduces Baltimores First 1.2T High Field Open MRI
2. Pfizer Declares A 20-Cent First-Quarter 2011 Dividend
3. Lilly Declares First-Quarter 2011 Dividend
4. First Patient Enrolled in Multi-Center Clinical Trial of the CorMatrix® ECM® for Pericardial Closure to Reduce the Incidence of New Onset Postoperative Atrial Fibrillation
5. Netsmart Technologies is First Behavioral Healthcare Software Provider to Attain Complete ARRA-Certified Electronic Health Record
6. Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human Btk-Inhibitor PCI-32765
7. Access Pharmaceuticals Updates MuGard Website With First Patient Testimonial Video
8. BugLab Launches Worlds First Handheld Non-invasive Optical Density Sensor
9. Inspiration Biopharmaceuticals Treats First Patient in Pivotal Study of OBI-1 for Acquired Hemophilia A
10. BMEYE Receives FDA Clearance to Launch ccNexfin, the First Totally Noninvasive Cardiovascular Monitor With BP, CO, and Masimo Rainbow SET(R) Technology in the United States
11. First-Line Use of Abilify Has More Than Doubled Over the Past Year for the Treatment of Newly-Diagnosed Patients in Bipolar Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... Amarantus BioScience Holdings, Inc. ... Regenerative Medicine, Neurology and Orphan Diseases, today announced that President & ... upcoming investor conferences: SeeThru Equity MicroCap Conference   ... New York City , NY When: Tuesday, May ... Conference   Where: Grand Hyatt Hotel, 109 East 42 ...
(Date:5/26/2016)... May 26, 2016   Change Healthcare ... analytics, network solutions and technology-enabled services designed ... entered into a strategic channel partnership with ... software solutions and revenue cycle management services ... and rehabilitation clinics to optimize revenue, operational ...
(Date:5/25/2016)... and GERMANTOWN, Maryland , May 25, 2016 ... ; Frankfurt Prime Standard: QIA) today announced that the company ... Diagnostics GmbH to develop and commercialize predictive assays in oncology. ... as a marker to predict effectiveness of anthracycline treatment in ... "We are pleased to partner with Therawis, which developed the ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... 2016 , ... This campaign aims to provide a path to improved education ... control and change. , As nearly 795,000 Americans suffering from a new or recurrent ... Plus, with an estimated 129,000 of these people dying from stroke, it’s become our ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... ... Mediaplanet to help educate the many who are unaware of the plight of ... aphasia will run within the “Stroke Awareness” campaign. , The link between stroke ...
(Date:5/27/2016)... ... 27, 2016 , ... Aimed at nurses and employees in ... courtesy of leaders in the nursing and health care industry. It also provides ... and associations—namely Jones & Bartlett Learning. , Jones & Bartlett Learning is adding ...
(Date:5/27/2016)... ... May 27, 2016 , ... Each year Standard ... Allison Outerbridge is this year’s Life University winner of a $2,500 ... university’s Student Leadership Awards ceremony. , Outerbridge is approaching her last quarter at ...
(Date:5/26/2016)... ... , ... Despite last week’s media reports hinting at a June rate hike ... March 2017 for an interest rate increase, according to Rajeev Dhawan of the Economic ... Federal Open Market Committee (FOMC) dot charts are of interest to the press for ...
Breaking Medicine News(10 mins):